5月15日,全球临床试验收录网站显示,百济神州启动了BGB-16673(catadegbrutinib)头对头Pirtobrutinib(匹妥布替尼)的III期临床试验(CaDAnCe-304)。BGB-16673是百济神州基于其嵌合式降解激活化合物(CDAC)技术平台开发的一款靶向BTK的蛋白降解靶向嵌合体(PROTAC)药物。临床前模型显示,BGB-16673能克服C481S耐药,具有高选择性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.